166 related articles for article (PubMed ID: 37706607)
21. Somatic MMR gene mutations as a cause for MSI-H sebaceous neoplasms in Muir-Torre syndrome-like patients.
Joly MO; Attignon V; Saurin JC; Desseigne F; Leroux D; Martin-Denavit T; Giraud S; Bonnet-Dupeyron MN; Faivre L; Auclair J; Grand-Masson C; Audoynaud C; Wang Q
Hum Mutat; 2015 Mar; 36(3):292-5. PubMed ID: 25504677
[TBL] [Abstract][Full Text] [Related]
22. Multiple benign adnexal tumours: Anything but benign.
McCarthy RL; Thomas CL; Isaacs F
Australas J Dermatol; 2019 Aug; 60(3):234-236. PubMed ID: 30671930
[TBL] [Abstract][Full Text] [Related]
23. Sebaceous neoplasms and the immunoprofile of mismatch-repair proteins as a screening target for syndromic cases.
Boennelycke M; Thomsen BM; Holck S
Pathol Res Pract; 2015 Jan; 211(1):78-82. PubMed ID: 25457183
[TBL] [Abstract][Full Text] [Related]
24. Sebaceous gland tumors of the eyelids and conjunctiva in the Muir-Torre syndrome: a clinicopathologic study of five cases and literature review.
Rishi K; Font RL
Ophthalmic Plast Reconstr Surg; 2004 Jan; 20(1):31-6. PubMed ID: 14752307
[TBL] [Abstract][Full Text] [Related]
25. Cystic sebaceous tumors as marker lesions for the Muir-Torre syndrome: a histopathologic and molecular genetic study.
Rütten A; Burgdorf W; Hügel H; Kutzner H; Hosseiny-Malayeri HR; Friedl W; Propping P; Kruse R
Am J Dermatopathol; 1999 Oct; 21(5):405-13. PubMed ID: 10535567
[TBL] [Abstract][Full Text] [Related]
26. Metachronous occurrence of colorectal cancer in a muir-torre syndrome patient presenting with recurrent sebaceous adenoma of the eyelid: case report and updated review of the literature.
Agiannidis C; Pana ZD; Molyva D; Kalokasidis K; Mixiou M
J Cutan Med Surg; 2012; 16(6):394-9. PubMed ID: 23149194
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of universal immunohistochemical screening of sebaceous neoplasms in a service setting.
Schon K; Rytina E; Drummond J; Simmonds J; Abbs S; Sandford R; Tischkowitz M
Clin Exp Dermatol; 2018 Jun; 43(4):410-415. PubMed ID: 29333623
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemistry, Molecular Biology, and Clinical Scoring for the Detection of Muir-Torre Syndrome in Cutaneous Sebaceous Tumors: Which Strategy?
Sinson H; Karayan-Tapon L; Godet J; Rivet P; Alleyrat C; Battistella M; Pierron H; Morel F; Lecron JC; Favot L; Frouin E
Dermatology; 2023; 239(6):889-897. PubMed ID: 37717564
[TBL] [Abstract][Full Text] [Related]
29. [Female patient with Muir-Torre syndrome].
Negraszus N; Jöhrens K; Bertelmann E
Ophthalmologe; 2010 Nov; 107(11):1059-62. PubMed ID: 20393721
[TBL] [Abstract][Full Text] [Related]
30. Muir-Torre syndrome: case report and review of the literature.
Ang JM; Alai NN; Ritter KR; Machtinger LA
Cutis; 2011 Mar; 87(3):125-8. PubMed ID: 21488569
[TBL] [Abstract][Full Text] [Related]
31. Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome.
Simic D; Dummer R; Freiberger SN; Ramelyte E; Barysch MJ
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065301
[TBL] [Abstract][Full Text] [Related]
32. Aggressive Extraocular Sebaceous Carcinoma of the Scalp Involving the Brain in a Patient With Muir-Torre Syndrome.
Hadravsky L; Kazakov DV; Stehlik J; Michal M; Curik R; Krupa P; Skalova A; Kacerovska D
Am J Dermatopathol; 2016 Aug; 38(8):618-22. PubMed ID: 26779764
[TBL] [Abstract][Full Text] [Related]
33. Reticulated acanthoma with sebaceous differentiation: another sebaceous neoplasm associated with Muir-Torre syndrome?
Shon W; Wolz MM; Newman CC; Bridges AG
Australas J Dermatol; 2014 Nov; 55(4):e71-3. PubMed ID: 23651324
[TBL] [Abstract][Full Text] [Related]
34. [Sebaceous tumors and Muir-Torre syndrome].
Bourlond F; Cribier B; Lipsker D; Velter C
Ann Dermatol Venereol; 2015; 142(6-7):456-9. PubMed ID: 25890836
[No Abstract] [Full Text] [Related]
35. Muir-Torre Syndrome with Novel Mutation in the MSH2 Gene.
Ustaoglu E; Agirgol S; Aymelek HS; Turhan EI
Acta Dermatovenerol Croat; 2023 Dec; 31(3):144-147. PubMed ID: 38439724
[TBL] [Abstract][Full Text] [Related]
36. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
[TBL] [Abstract][Full Text] [Related]
37. Sebaceous gland adenoma of the tarsal conjunctiva in a patient with Muir-Torre syndrome.
Font RL; Rishi K
Ophthalmology; 2003 Sep; 110(9):1833-6. PubMed ID: 13129885
[TBL] [Abstract][Full Text] [Related]
38. Muir-Torre syndrome: sebaceous carcinoma concurrent with colon cancer in a kidney transplant recipient; a case report.
Tomonari M; Shimada M; Nakada Y; Yamamoto I; Itoh M; Koike Y; Kobayashi A; Miki J; Yamada H; Kimura T; Saito S; Sugano K; Sekine S; Yamamoto H; Asahina A; Yokoo T
BMC Nephrol; 2019 Oct; 20(1):394. PubMed ID: 31664942
[TBL] [Abstract][Full Text] [Related]
39. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm.
Abbas O; Mahalingam M
J Cutan Pathol; 2009 Jun; 36(6):613-9. PubMed ID: 19515040
[TBL] [Abstract][Full Text] [Related]
40. An individual with Muir-Torre syndrome found to have a pathogenic MSH6 gene mutation.
Arnold A; Payne S; Fisher S; Fricker D; Soloway J; White SM; Novelli M; MacDonald K; Mackay J; Groves R; Canham N
Fam Cancer; 2007; 6(3):317-21. PubMed ID: 17323113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]